<bill session="110" type="s" number="438" updated="2009-01-09T12:05:08-05:00">
	<status><introduced date="1170133200" datetime="2007-01-30"/></status>

	<introduced date="1170133200" datetime="2007-01-30"/>
	<titles>
		<title type="short" as="introduced">Fair Prescription Drug Competition Act</title>
		<title type="official" as="introduced">A bill to amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs.</title>
	</titles>
	<sponsor id="300084"/>
	<cosponsors>
		<cosponsor id="300065" joined="2007-01-30"/>
		<cosponsor id="300093" joined="2007-03-07"/>
		<cosponsor id="300087" joined="2007-01-30"/>
		<cosponsor id="300061" joined="2007-01-30"/>
	</cosponsors>
	<actions>
		<action date="1170133200" datetime="2007-01-30"><text>Sponsor introductory remarks on measure. (CR S1351-1352)</text></action>
		<action date="1170133200" datetime="2007-01-30"><text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text><reference label="text of measure as introduced" ref="CR S1352"/></action>
	</actions>
	<committees>

	</committees>
	<relatedbills>

	</relatedbills>
	<subjects>

	</subjects>
	<amendments>

	</amendments>
	<summary>
	1/30/2007--Introduced.<br/>Fair Prescription Drug Competition Act - Amends the Federal Food, Drug, and Cosmetic Act to prohibit a holder of a new, approved drug application from commencing to manufacture, market, sell, or distribute a generic version of such drug from the time of the receipt of notice from the generic manufacturer that an abbreviated new drug application has been submitted for approval until the expiration or forfeiture of the exclusivity period granted to the generic manufacturer. 
	</summary>
</bill>
